Glypican1: A potential cancer biomarker for nanotargeted therapy

Abhay Dev Tripathi; Soumya Katiyar; Abha Mishra

doi:10.1016/j.drudis.2023.103660

Glypican1: A potential cancer biomarker for nanotargeted therapy

Drug Discov Today. 2023 Aug;28(8):103660. doi: 10.1016/j.drudis.2023.103660. Epub 2023 Jun 9.

Authors

Abhay Dev Tripathi¹, Soumya Katiyar¹, Abha Mishra²

Affiliations

¹ School of Biochemical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi 221 005, India.
² School of Biochemical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi 221 005, India. Electronic address: abham.bce@itbhu.ac.in.

PMID: 37301249
DOI: 10.1016/j.drudis.2023.103660

Abstract

Glypicans (GPCs) are generally involved in cellular signaling, growth and proliferation. Previous studies reported their roles in cancer proliferation. GPC1 is a co-receptor for a variety of growth-related ligands, thereby stimulating the tumor microenvironment by promoting angiogenesis and epithelial-mesenchymal transition (EMT). This work reviews GPC1-biomarker-assisted drug discovery by the application of nanostructured materials, creating nanotheragnostics for targeted delivery and application in liquid biopsies. The review includes details of GPC1 as a potential biomarker in cancer progression as well as a potential candidate for nano-mediated drug discovery.

Keywords: Glypican1; cancer biomarker; diagnostic nanotechnology; drug delivery; therapeutic nanotechnology.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor*
Cell Proliferation
Neoplasms* / drug therapy

Substances

Biomarkers, Tumor